HAL will be down for maintenance from Friday, June 10 at 4pm through Monday, June 13 at 9am. More information
Skip to Main content Skip to Navigation
Journal articles

Long-term effectiveness of MenAfriVac

Abstract : A conjugate vaccine for Neisseria meningitidis serogroup A (MenAfriVac) was introduced through mass campaigns in people aged 1–29 years in the African meningitis belt and is now being added to national infant immunisation programmes. 1 Following the mass campaigns in 2010–17, incidence of N meningitidis serogroup A meningitis has declined from a hyperendemic pattern with regular epidemics to a few sporadic cases. 2 The hope is that control of the disease will be long lasting. The mechanism for such control would be the initial interruption of circulation of N meningitidis serogroup A in the population through the effect of the vaccine against asymptomatic nasopharyngeal infection, followed by sustained direct protection against disease, including in new birth cohorts. The duration of persistence of antibodies is a major variable in this scheme.
Document type :
Journal articles
Complete list of metadata

Contributor : Scd Ehesp Connect in order to contact the contributor
Submitted on : Friday, January 31, 2020 - 10:06:26 AM
Last modification on : Thursday, April 7, 2022 - 10:10:30 AM




Judith E. Mueller. Long-term effectiveness of MenAfriVac. The Lancet Infectious Diseases, New York, NY : Elsevier Science ; The Lancet Pub. Group, 2001-, 2019, 19 (3), pp.228-229. ⟨10.1016/S1473-3099(18)30725-4⟩. ⟨hal-02462110⟩



Record views